BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31093341)

  • 1. Systemic therapy for recurrent or metastatic salivary gland malignancies.
    Chintakuntlawar AV; Okuno SH; Price KA
    Cancers Head Neck; 2016; 1():11. PubMed ID: 31093341
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Bhushan K; Sharma ML; Gupta DK
    Indian J Otolaryngol Head Neck Surg; 2024 Feb; 76(1):123-129. PubMed ID: 38440426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy for salivary gland malignancy: current status and future perspectives.
    Imamura Y; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ota I; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Yokota T; Okano S; Tanaka K; Onoe T; Ariizumi Y; Homma A
    Jpn J Clin Oncol; 2022 Apr; 52(4):293-302. PubMed ID: 35134985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents.
    Agulnik M; Siu LL
    Curr Med Chem Anticancer Agents; 2004 Nov; 4(6):543-51. PubMed ID: 15579019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.
    Surakanti SG; Agulnik M
    Semin Oncol; 2008 Jun; 35(3):309-19. PubMed ID: 18544445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel therapeutic approaches for salivary gland carcinomas].
    Nachtsheim L; Prinz J; Arolt C; Quaas A; Meyer M; Klußmann JP; Wolber P
    Laryngorhinootologie; 2022 Nov; 101(11):876-881. PubMed ID: 35320850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A molecular guide to systemic therapy in salivary gland carcinoma.
    Weaver AN; Lakritz S; Mandair D; Ulanja MB; Bowles DW
    Head Neck; 2023 May; 45(5):1315-1326. PubMed ID: 36859797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of salivary gland carcinomas - a review.
    Wang X; Luo Y; Li M; Yan H; Sun M; Fan T
    Oncotarget; 2017 Jan; 8(3):3946-3956. PubMed ID: 27992367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Salivary gland malignancies-highlights of the 2019 ASCO Annual Meeting].
    Doescher J; Schuler PJ; Greve J; Meyer MF; Weissinger S; Hoffmann TK; Laban S
    HNO; 2019 Dec; 67(12):931-934. PubMed ID: 31628530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
    Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy in the management of metastatic or advanced salivary gland cancers.
    Lagha A; Chraiet N; Ayadi M; Krimi S; Allani B; Rifi H; Raies H; Mezlini A
    Oral Oncol; 2012 Oct; 48(10):948-957. PubMed ID: 22698431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours.
    Cros J; Sbidian E; Hans S; Roussel H; Scotte F; Tartour E; Brasnu D; Laurent-Puig P; Bruneval P; Blons H; Badoual C
    Ann Oncol; 2013 Oct; 24(10):2624-2629. PubMed ID: 23933559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
    Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
    Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy in the management of metastatic or advanced salivary gland cancers.
    Lagha A; Chraiet N; Ayadi M; Krimi S; Allani B; Rifi H; Raies H; Mezlini A
    Head Neck Oncol; 2012 May; 4():19. PubMed ID: 22558945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update and perspectives on non-surgical treatment of salivary gland malignancies.
    Airoldi M; Cortesina G; Giordano C; Pedani F; Cavalot A; Marcato P; Beatrice F; Bumma C
    Acta Otorhinolaryngol Ital; 2003 Oct; 23(5):368-76. PubMed ID: 15108487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer.
    Mueller SK; Haderlein M; Lettmaier S; Agaimy A; Haller F; Hecht M; Fietkau R; Iro H; Mantsopoulos K
    J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary gland cancers: biology and molecular targets for therapy.
    Bell D; Hanna EY
    Curr Oncol Rep; 2012 Apr; 14(2):166-74. PubMed ID: 22246609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy in the palliative management of advanced salivary gland cancers.
    Laurie SA; Licitra L
    J Clin Oncol; 2006 Jun; 24(17):2673-8. PubMed ID: 16763282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
    Dodd RL; Slevin NJ
    Oral Oncol; 2006 Sep; 42(8):759-69. PubMed ID: 16757203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.